enzyme replacement therapy (Sigilon Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameenzyme replacement therapy (Sigilon Therapeutics)
Drug Alias Nameiduronidase enzyme replacement therapy (Sigilon Therapeutics)enzyme replacement therapy (Sigilon)SIG-005 (Sigilon)
ClassificationBiologics > Protein drugs > EnzymeCell and gene therapy > Cell therapy
Mechanisms of ActionAlpha-L-iduronidase stimulants
TargetsAlpha-L-iduronidase
Therapy Area/IndicationsHurler-Scheie syndromeLysosomal Storage DiseasesMucopolysaccharidosis I
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEuropeUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSigilon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSigilon Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHurler-Scheie syndromeLysosomal Storage DiseasesMucopolysaccharidosis I

Other Information

ATC CodeN/A
Related LinksN/A